Shandong Xinhua Pharmaceutical (00719) held an Extraordinary General Meeting on 24 October 2025 at No. 1 Lutai Ave., Hi-tech District, Zibo City, Shandong Province, the PRC. According to official data, 532 shareholders attended in person, by proxy, or via network voting, representing a total of 234,714,588 voting shares, or about 34.03% of the company’s issued share capital.

All resolutions detailed in the 2 October 2025 notice were approved, including amendments to the Articles of Association and related rules and procedures. At the time of the meeting, Shandong Xinhua Pharmaceutical had 689,776,535 shares in issue, comprising 494,776,535 A shares and 195,000,000 H shares. Each of the passed special resolutions received more than two-thirds of the votes cast.

With the resolutions passed, the term of the 11th Supervisory Committee concluded, and the company ceased to establish a new Supervisory Committee. Oversight responsibilities once handled by this committee have been transferred to the Audit Committee under the Board of Directors.